IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Stock Profile — Insider Trades & Financials

Revenue$99.3M

Net Income-$47.3M

EPS$-0.29

Market Cap$6.6B

Price Performance

Historical data including institutional events

Company Profile

Frederick Vogt

CEO & Executive Director

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.

Founded: 2007
Employees: 319
Headquarters: SAN CARLOS, CA, United States
Website: www.iovance.com

Peer ComparisonRevenue ($B)

▾

Loading company sections...

Revenue$99.3M

Net Income-$47.3M

EPS$-0.29

Market Cap$6.6B

Price Performance

Historical data including institutional events

Company Profile

Frederick Vogt

CEO & Executive Director

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.

Founded: 2007
Employees: 319
Headquarters: SAN CARLOS, CA, United States
Website: www.iovance.com

Peer ComparisonRevenue ($B)

▾

Cross-Section Event Timeline

INSIDERS · CONGRESS · EARNINGS

INSIDER EXERCISE / CONVERSIONIgor Bilinsky (Chief Operating Officer) EXERCISE / CONVERSION IOVASep 1, 2026

INSIDER TAX WITHHOLDINGIgor Bilinsky (Chief Operating Officer) TAX WITHHOLDING IOVASep 1, 2026

INSIDER EXERCISE / CONVERSIONRaj K. Puri (Chief Regulatory Officer) EXERCISE / CONVERSION IOVASep 1, 2026

INSIDER TAX WITHHOLDINGRaj K. Puri (Chief Regulatory Officer) TAX WITHHOLDING IOVASep 8, 2026

INSIDER EXERCISE / CONVERSIONRaj K. Puri (Chief Regulatory Officer) EXERCISE / CONVERSION IOVASep 8, 2026

INSIDER TAX WITHHOLDINGIgor Bilinsky (Chief Operating Officer) TAX WITHHOLDING IOVASep 8, 2026

INSIDER EXERCISE / CONVERSIONIgor Bilinsky (Chief Operating Officer) EXERCISE / CONVERSION IOVASep 8, 2026

INSIDER EXERCISE / CONVERSIONFrederick G. Vogt (Interim CEO & General Counsel) EXERCISE / CONVERSION IOVASep 8, 2026

INSIDER TAX WITHHOLDINGFrederick G. Vogt (Interim CEO & General Counsel) TAX WITHHOLDING IOVASep 8, 2026

INSIDER EXERCISE / CONVERSIONFrederick G. Vogt (Interim CEO & General Counsel) EXERCISE / CONVERSION IOVASep 8, 2026

INSIDER GRANT / AWARDNoah Berkowitz (Chief Medical Officer) GRANT / AWARD IOVASep 30, 2026

⚡

Core Efficiency

ROE?

-6.43%

ROA?

-5.17%

D/E Ratio?

0.24

Op. Margin?

-52.26%

📊

Profitability Ratios

Net Margin?

-47.64%

Current Ratio?

4.34

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Oct 26, 2026 (in 13 days)

Quarterly Report (10-Q) — Based on filing pattern

Oct 26, 2026

Predicted10-Q

Aug 6, 2026

10-QQ2 202637d after period end

May 7, 2026

10-QQ1 202637d after period end

Feb 24, 2026

10-KQ4 202511d after period end

Nov 6, 2025

10-QQ3 202522d after period end

Aug 7, 2025

10-QQ2 202538d after period end

May 8, 2025

10-QQ1 20258d after period end

Data Freshness

Financial Data

2mo ago

Latest filing: 2026-08-06

SEC Metadata

2mo ago

Latest filing: 2026-08-06

Loading company sections...

IOVANCE BIOTHERAPEUTICS, INC.

Price Performance

Company Profile

IOVANCE BIOTHERAPEUTICS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

IOVANCE BIOTHERAPEUTICS, INC.

Price Performance

Company Profile

The morning brief, before the bell.

IOVANCE BIOTHERAPEUTICS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades